News | July 06, 2022
Vaccizone selects Exothera for GMP manufacturing of its SARS?CoV?2 vaccine
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
This investment will facilitate a Cipla entity's strategic participation in the Poe diagnostics and AMR space through the design, development, and manufacturing of microfluidics-based technologies
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
To address the preventive & primary healthcare delivery gaps in India
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
The study was conducted in equal laboratory conditions in the Spallanzani Institute in Italy on comparable sera samples from individuals vaccinated with Sputnik V and Pfizer with a similar level of IgG antibodies and virus-neutralizing activity (VNA) against Wuhan variant.
Pfizer calls upon global health leaders and organizations to join the Accord, bringing their expertise and resources to close the health equity gap
Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Subscribe To Our Newsletter & Stay Updated
